Anaphylaxis to three humanized antibodies for severe asthma: a case study

Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare.

Source: Allergy, Asthma and Clinical Immunology - June 10, 2020 Category: Allergy & Immunology Authors: Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito and Kazuhisa Takahashi Tags: Case report Source Type: research